Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura
about
Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic reviewChildhood immune thrombocytopenia: Clinical presentation and managementLeveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States.Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.Management of patients with refractory immune thrombocytopenic purpura.Treatment with rituximab in benign and malignant hematologic disorders in children.Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency.Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysisRituximab in the treatment of autoimmune haematological disorders.Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpuraResponse to mercaptopurine for refractory autoimmune cytopenias in children.One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.Repeated courses of rituximab in chronic ITP: Three different regimens.Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopeniaManagement of immune thrombocytopenic purpura in children: potential role of novel agents.Rapid update on childhood immune thrombocytopenic purpure.Use of romiplostim for primary immune thrombocytopenia in children.Sequence of treatments for adults with primary immune thrombocytopenia.Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.Rituximab for children with immune thrombocytopenia: a systematic review.Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura.Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions.Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.Spontaneous improvement of chronic immune thrombocytopenia in children: experience of 56 patients at a single institute.Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience.Clinical practice: immune thrombocytopenia in paediatrics.Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.Rituximab therapy for refractory autoimmune thrombocytopenia in patients with systemic lupus erythematosus.Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.Health-related quality of life in children with newly diagnosed immune thrombocytopeniaRomiplostim as a treatment for immune thrombocytopenia: a review.How I manage Evans Syndrome and AIHA cases in children.Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?Novel therapies for immune tolerance in haemophilia A.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesAntibody therapy of pediatric B-cell lymphomaRituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis
P2860
Q24643047-CD7CDDE9-B880-4786-8196-C4733B1D4081Q26826853-8EC94C2C-F16E-4034-8427-A650DE99F0F9Q27023294-3A51345F-F946-4E71-BD53-445E3836AD3EQ30583310-AC866D1A-43AB-49B5-8204-614C1CEDD304Q31089024-089572BA-15D7-44C9-839C-7AABBD8150B3Q33372113-6429EA40-DB14-4E10-A371-5527CA99B019Q33374660-464DE059-0EBB-4004-9E97-FE8FBB59EDE7Q33375244-50017514-F5E9-4C51-8703-2A4BC28B1138Q33376705-97F779F8-CE63-49DE-A104-9225C0BAF11AQ33378854-88301681-5D3E-43A1-AEF3-2A992A0CE0F7Q33380732-218E30C1-E3CC-41F3-B78A-9E3D812B4766Q33380897-A33384ED-5C62-45BB-A5D0-811F379E5EDCQ33381700-9A8CFD16-D379-4204-BD24-6BECFE6EAEDBQ33386117-5AFB2A23-5B01-4C53-BAA0-B610AA91824AQ33395792-80F2E431-D429-4FDC-A78C-57E745745393Q33395863-94556052-76EE-46A2-A632-CD3E39EFD0C9Q33397751-A83EC73E-47E5-47D3-B588-1DA7A144457FQ33399983-37EB1842-136C-4E22-9391-BA59B64033EEQ33400072-48A577D7-07E7-4497-A927-70E54FDCFE94Q33401100-585C7418-C683-442F-B01A-7CD51BEEA27BQ33401605-9053FA9A-DA22-4FC6-961A-69EA9EE4260BQ33402069-7956AD44-9AF5-4C18-8514-D35FAA8687D0Q33402387-7B0C0BA8-E3A6-4223-8798-F9B50C7862CBQ33402453-333F9B3B-F334-49C7-82D1-0972329119CDQ33404073-8DA15DE3-1E60-4CB1-AAC0-4691C091D78EQ33411082-41E61C6B-0F9F-4695-BEDA-7DD2E463187DQ33412475-7BABD897-AA66-4B9A-AC91-7D9777F6B2A0Q33413781-AC4A5254-2271-4763-8C47-0BE88F461575Q33414696-A3581EBF-CFE4-4D1A-AC72-A8E81C31845AQ33414722-6B154CC0-B3C8-4CDC-BD7C-56A71F4D1C0EQ33416038-7F5EEB5E-AB87-43A0-B8D9-5914D068B3EBQ33420059-64B2B47E-6686-4054-ABE2-2052EB9B0226Q33428041-1ACC4822-B63F-45C6-A550-50185D3C7AD7Q33431689-F08D190C-4592-425F-8F26-1F4B87F891A7Q35237511-05CE13C4-54B7-4810-84C1-4B3C73B4BC8EQ36661858-947A5036-2C39-4B8C-B040-B363CE78EA1BQ36724093-534675B0-B6D6-48DE-83E4-26BAB4258A3DQ36732959-1AF8EFFE-1FB3-483A-A02D-07AD1BC49816Q37100817-52CF2B6F-F9F7-4F02-B8FB-DD8C5C75A864Q37207120-C3E4B86A-224F-438B-AA95-6E4D5D31D6C2
P2860
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prospective phase 1/2 study of ...... mmune thrombocytopenic purpura
@ast
Prospective phase 1/2 study of ...... mmune thrombocytopenic purpura
@en
type
label
Prospective phase 1/2 study of ...... mmune thrombocytopenic purpura
@ast
Prospective phase 1/2 study of ...... mmune thrombocytopenic purpura
@en
prefLabel
Prospective phase 1/2 study of ...... mmune thrombocytopenic purpura
@ast
Prospective phase 1/2 study of ...... mmune thrombocytopenic purpura
@en
P2093
P2860
P1433
P1476
Prospective phase 1/2 study of ...... mmune thrombocytopenic purpura
@en
P2093
Adonis N Lorenzana
Bertil E Glader
Brigitta U Mueller
Carolyn M Bennett
Daniel D Kinnamon
Donald H Mahoney
Ellis J Neufeld
George R Buchanan
Hadi Sawaf
Henry A Feldman
P2860
P304
P356
10.1182/BLOOD-2005-08-3518
P407
P577
2005-12-13T00:00:00Z